Reconstituted High-Density Lipoprotein Modulates Activation of Human Leukocytes

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Spirig, Rolf ^a,b   Schaub, Alexander ^b   Kropf, Alain ^b   Miescher, Sylvia ^b   Spycher, Martin O ^b   Rieben, Robert ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b ZLB Behring AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; B7 ANTIGEN; CCL 2 PROTEIN; CCL 4 PROTEIN; CCL 5 PROTEIN; CD14 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; CHEMOKINE; CXCL 10 PROTEIN; CXCL 9 PROTEIN; HIGH DENSITY LIPOPROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 12P40; INTERLEUKIN 15; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 7; PHYTOHEMAGGLUTININ; RECONSTITUTED HIGH DENSITY LIPOPROTEIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD DONOR; CELL SURFACE; CELLULAR IMMUNITY; CHEMOKINE SYNTHESIS; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DOSE RESPONSE; GRANULOCYTE; HUMAN; HUMAN CELL; INNATE IMMUNITY; LEUKOCYTE ACTIVATION; MONOCYTE; PROTEIN SYNTHESIS; UPREGULATION; VOLUNTEER;

ANTIGENS, CD14; ANTIGENS, CD86; CHEMOKINES; DENDRITIC CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; GRANULOCYTES; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; KINETICS; LEUKOCYTES; LIPOPROTEINS, HDL; MONOCYTES; NF-KAPPA B; TOLL-LIKE RECEPTOR 2; UP-REGULATION;

EID: 84881531213     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071235     Document Type: Article

References (73)

1. Tardif JC, Gregoire J, L′Allier PL, Ibrahim R, Lesperance J, et al. (2007) Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 297: 1675-1682. 297.15.jpc70004 [pii];10.10 01/jama.297.15.jpc70004 [doi].
2. Shaw JA, Bobik A, Murphy A, Kanellakis P, Blombery P, et al. (2008) Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque. Circ Res 103: 1084-1091 CIRCRESAHA.108.182063 [pii];10.1161/CIRCRESAHA.108.182063 [doi].
3. Wadham C, Albanese N, Roberts J, Wang L, Bagley CJ, et al. (2004) High-density lipoproteins neutralize C-reactive protein proinflammatory activity. Circulation 109: 2116-2122 10.1161/01.CIR.0000127419.45975.26 [doi];01.CIR.0000127419.45975.26 [pii].
4. Viswambharan H, Ming XF, Zhu S, Hubsch A, Lerch P, et al. (2004) Reconstituted high-density lipoprotein inhibits thrombin-induced endothelial tissue factor expression through inhibition of RhoA and stimulation of phosphatidylinositol 3-kinase but not Akt/endothelial nitric oxide synthase. Circ Res 94: 918-925 10.1161/01.RES.0000124302.20396.B7 [doi];01.RES.0000124302.20396.B7 [pii].
5. Spieker LE, Sudano I, Hurlimann D, Lerch PG, Lang MG, et al. (2002) High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 105: 1399-1402.
6. Calabresi L, Rossoni G, Gomaraschi M, Sisto F, Berti F, et al. (2003) High-density lipoproteins protect isolated rat hearts from ischemia-reperfusion injury by reducing cardiac tumor necrosis factor-alpha content and enhancing prostaglandin release. Circ Res 92: 330-337.
7. Kiya Y, Miura S, Imaizumi S, Uehara Y, Matsuo Y, et al. (2009) Reconstituted high-density lipoprotein attenuates postinfarction left ventricular remodeling in rats. Atherosclerosis 203: 137-144 S0021-9150(08)00390-0 [pii];10.1016/j.atherosclerosis.2008.05.056 [doi].
8. Yvan-Charvet L, Pagler T, Gautier EL, Avagyan S, Siry RL, et al. (2010) ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science 328: 1689-1693 science.1189731 [pii];10.1126/science.1189731 [doi].
9. Sun Y, Ishibashi M, Seimon T, Lee M, Sharma SM, et al. (2009) Free cholesterol accumulation in macrophage membranes activates Toll-like receptors and p38 mitogen-activated protein kinase and induces cathepsin K. Circ Res. 104: 455-465 CIRCRESAHA.108.182568 [pii];10.1161/CIRCRESAHA.108.182568 [doi].
10. Platt JL, Dalmasso AP, Lindman BJ, Ihrcke NS, Bach FH, (1991) The role of C5a and antibody in the release of heparan sulfate from endothelial cells. Eur J Immunol 21: 2887-2890 10.1002/eji.1830211135 [doi].
11. Ihrcke NS, Platt JL, (1996) Shedding of heparan sulfate proteoglycan by stimulated endothelial cells: evidence for proteolysis of cell-surface molecules. J Cell Physiol 168: 625-637 10.1002/(SICI)1097-4652(199609)168:3<625::AID-JCP15>3.0.CO;2-Y [pii];10.1002/(SICI)1097-4652(199609)168:3<625::AID-JCP15>3.0.CO;2-Y [doi].
12. Platt JL, Vercellotti GM, Lindman BJ, Oegema TR Jr, Bach FH, et al. (1990) Release of heparan sulfate from endothelial cells. Implications for pathogenesis of hyperacute rejection. J Exp Med 171: 1363-1368.
13. Luke HJ, Prehm P, (1999) Synthesis and shedding of hyaluronan from plasma membranes of human fibroblasts and metastatic and non-metastatic melanoma cells. Biochem J 343 Pt 1: 71-75.
14. Leemans JC, Stokman G, Claessen N, Rouschop KM, Teske GJ, et al. (2005) Renal-associated TLR2 mediates ischemia/reperfusion injury in the kidney. J Clin Invest 115: 2894-2903 10.1172/JCI22832 [doi].
15. Wu H, Chen G, Wyburn KR, Yin J, Bertolino P, et al. (2007) TLR4 activation mediates kidney ischemia/reperfusion injury. J Clin Invest 117: 2847-2859 10.1172/JCI31008 [doi].
16. Michelsen KS, Doherty TM, Shah PK, Arditi M (2004) TLR signaling: an emerging bridge from innate immunity to atherogenesis. J Immunol 173: 5901-5907. 173/10/5901 [pii].
17. Wyss CA, Neidhart M, Altwegg L, Spanaus KS, Yonekawa K, et al. (2010) Cellular actors, Toll-like receptors, and local cytokine profile in acute coronary syndromes. Eur Heart J 31: 1457-1469 ehq084 [pii];10.1093/eurheartj/ehq084 [doi].
18. Nathan C, (2006) Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol 6: 173-182 nri1785 [pii];10.1038/nri1785 [doi].
19. Bell D, Jackson M, Nicoll JJ, Millar A, Dawes J, et al. (1990) Inflammatory response, neutrophil activation, and free radical production after acute myocardial infarction: effect of thrombolytic treatment. Br Heart J 63: 82-87.
20. Yasunami Y, Kojo S, Kitamura H, Toyofuku A, Satoh M, et al. (2005) Valpha14 NK T cell-triggered IFN-gamma production by Gr-1+CD11b+ cells mediates early graft loss of syngeneic transplanted islets. J Exp Med 202: 913-918 jem.20050448 [pii];10.1084/jem.20050448 [doi].
21. Mantovani A, Cassatella MA, Costantini C, Jaillon S, (2011) Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol 11: 519-531 nri3024 [pii];10.1038/nri3024 [doi].
22. Randolph GJ, Jakubzick C, Qu C, (2008) Antigen presentation by monocytes and monocyte-derived cells. Curr Opin Immunol 20: 52-60 S0952-7915(07)00181-1 [pii];10.1016/j.coi.2007.10.010 [doi].
23. Hansson GK, Robertson AK, Soderberg-Naucler C, (2006) Inflammation and atherosclerosis. Annu Rev Pathol 1: 297-329 10.1146/annurev.pathol.1.110304.100100 [doi].
24. Sung FL, Zhu TY, Au-Yeung KK, Siow YL, O K, (2002) Enhanced MCP-1 expression during ischemia/reperfusion injury is mediated by oxidative stress and NF-kappaB. Kidney Int 62: 1160-1170 kid577 [pii];10.1111/j.1523-1755.2002.kid577.x [doi].
25. Yue TL, Chen J, Bao W, Narayanan PK, Bril A, et al. (2001) In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation 104: 2588-2594.
26. Banchereau J, Steinman RM, (1998) Dendritic cells and the control of immunity. Nature 392: 245-252 10.1038/32588 [doi].
27. Curtsinger JM, Mescher MF, (2010) Inflammatory cytokines as a third signal for T cell activation. Curr Opin Immunol 22: 333-340 S0952-7915(10)00047-6 [pii];10.1016/j.coi.2010.02.013 [doi].
28. Lerch PG, Foertsch V, Hodler G, Bolli R, (1996) Production and characterization of a reconstituted high density lipoprotein for therapeutic applications. Vox Sang 71: 155-164.
29. Obregon C, Dreher D, Kok M, Cochand L, Kiama GS, et al. (2003) Human alveolar macrophages infected by virulent bacteria expressing SipB are a major source of active interleukin-18. Infect Immun 71: 4382-4388.
30. Obregon C, Rothen-Rutishauser B, Gitahi SK, Gehr P, Nicod LP, (2006) Exovesicles from human activated dendritic cells fuse with resting dendritic cells, allowing them to present alloantigens. Am J Pathol 169: 2127-2136 S0002-9440(10)62672-7 [pii];10.2353/ajpath.2006.060453 [doi].
31. Spirig R, van Kooten C, Obregon C, Nicod L, Daha M, et al. (2008) The complement inhibitor low molecular weight dextran sulfate prevents TLR4-induced phenotypic and functional maturation of human dendritic cells. J Immunol 181: 878-890. 181/2/878 [pii].
32. Mentzer SJ, Guyre PM, Burakoff SJ, Faller DV, (1986) Spontaneous aggregation as a mechanism for human monocyte purification. Cell Immunol 101: 312-319.
33. Sallusto F, Lanzavecchia A, (1994) Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 179: 1109-1118.
34. Spirig R, Djafarzadeh S, Regueira T, Shaw SG, von Garnier C, et al. (2010) Effects of TLR agonists on the hypoxia-regulated transcription factor HIF-1alpha and dendritic cell maturation under normoxic conditions. PLoS ONE 5: e0010983 10.1371/journal.pone.0010983 [doi].
35. Termeer C, Benedix F, Sleeman J, Fieber C, Voith U, et al. (2002) Oligosaccharides of Hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med 195: 99-111.
36. Roebuck KA, Finnegan A, (1999) Regulation of intercellular adhesion molecule-1 (CD54) gene expression. J Leukoc Biol 66: 876-888.
37. Dzionek A, Fuchs A, Schmidt P, Cremer S, Zysk M, et al. (2000) BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol 165: 6037-6046.
38. Taylor KR, Yamasaki K, Radek KA, Di NA, Goodarzi H, et al. (2007) Recognition of hyaluronan released in sterile injury involves a unique receptor complex dependent on Toll-like receptor 4, CD44, and MD-2. J Biol Chem 282: 18265-18275 M606352200 [pii];10.1074/jbc.M606352200 [doi].
39. Schwandner R, Dziarski R, Wesche H, Rothe M, Kirschning CJ, (1999) Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. J Biol Chem 274: 17406-17409.
40. Akira S, Takeda K, (2004) Toll-like receptor signalling. Nat Rev Immunol 4: 499-511 10.1038/nri1391 [doi];nri1391 [pii].
41. Pajkrt D, Doran JE, Koster F, Lerch PG, Arnet B, et al. (1996) Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med 184: 1601-1608.
42. Nicholls SJ, Dusting GJ, Cutri B, Bao S, Drummond GR, et al. (2005) Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation 111: 1543-1550 01.CIR.0000159351.95399.50 [pii];10.1161/01.CIR.0000159351.95399.50 [doi].
43. Bursill CA, Castro ML, Beattie DT, Nakhla S, van der Vorst E, et al. (2010) High-density lipoproteins suppress chemokines and chemokine receptors in vitro and in vivo. Arterioscler Thromb Vasc Biol 30: 1773-1778 ATVBAHA.110.211342 [pii];10.1161/ATVBAHA.110.211342 [doi].
44. Murphy AJ, Woollard KJ, Suhartoyo A, Stirzaker RA, Shaw J, et al. (2011) Neutrophil activation is attenuated by high-density lipoprotein and apolipoprotein A-I in in vitro and in vivo models of inflammation. Arterioscler Thromb Vasc Biol 31: 1333-1341 ATVBAHA.111.226258 [pii];10.1161/ATVBAHA.111.226258 [doi].
45. Perrin-Cocon L, Diaz O, Carreras M, Dollet S, Guironnet-Paquet A, et al. (2012) High-density lipoprotein phospholipids interfere with dendritic cell Th1 functional maturation. Immunobiology 217: 91-99 S0171-2985(11)00171-9 [pii];10.1016/j.imbio.2011.07.030 [doi].
46. Tolle M, Pawlak A, Schuchardt M, Kawamura A, Tietge UJ, et al. (2008) HDL-associated lysosphingolipids inhibit NAD(P)H oxidase-dependent monocyte chemoattractant protein-1 production. Arterioscler Thromb Vasc Biol 28: 1542-1548 ATVBAHA.107.161042 [pii];10.1161/ATVBAHA.107.161042 [doi].
47. Hyka N, Dayer JM, Modoux C, Kohno T, Edwards CK III, et al. (2001) Apolipoprotein A-I inhibits the production of interleukin-1beta and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes. Blood 97: 2381-2389.
48. Kim KD, Lim HY, Lee HG, Yoon DY, Choe YK, et al. (2005) Apolipoprotein A-I induces IL-10 and PGE2 production in human monocytes and inhibits dendritic cell differentiation and maturation. Biochem Biophys Res Commun 338: 1126-1136 S0006-291X(05)02310-7 [pii];10.1016/j.bbrc.2005.10.065 [doi].
49. Perrin-Cocon L, Diaz O, Carreras M, Dollet S, Guironnet-Paquet A, et al. (2012) High-density lipoprotein phospholipids interfere with dendritic cell Th1 functional maturation. Immunobiology 217: 91-99 S0171-2985(11)00171-9 [pii];10.1016/j.imbio.2011.07.030 [doi].
50. Veillard NR, Kwak B, Pelli G, Mulhaupt F, James RW, et al. (2004) Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ Res 94: 253-261 10.1161/01.RES.0000109793.17591.4E [doi];01.RES.0000109793.17591.4E [pii].
51. Goossens P, Gijbels MJ, Zernecke A, Eijgelaar W, Vergouwe MN, et al. (2010) Myeloid type I interferon signaling promotes atherosclerosis by stimulating macrophage recruitment to lesions. Cell Metab 12: 142-153 S1550-4131(10)00232-9 [pii];10.1016/j.cmet.2010.06.008 [doi].
52. Braunersreuther V, Pellieux C, Pelli G, Burger F, Steffens S, et al. (2010) Chemokine CCL5/RANTES inhibition reduces myocardial reperfusion injury in atherosclerotic mice. J Mol Cell Cardiol 48: 789-798 S0022-2828(09)00319-8 [pii];10.1016/j.yjmcc.2009.07.029 [doi].
53. Dewald O, Zymek P, Winkelmann K, Koerting A, Ren G, et al. (2005) CCL2/Monocyte Chemoattractant Protein-1 regulates inflammatory responses critical to healing myocardial infarcts. Circ Res 96: 881-889 01.RES.0000163017.13772.3a [pii];10.1161/01.RES.0000163017.13772.3a [doi].
54. Freitas MC, Uchida Y, Lassman C, Danovitch GM, Busuttil RW, et al. (2011) Type I interferon pathway mediates renal ischemia/reperfusion injury. Transplantation 92: 131-138 10.1097/TP.0b013e318220586e [doi].
55. Trinchieri G, (2003) Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3: 133-146 10.1038/nri1001 [doi];nri1001 [pii].
56. Bayry J, Lacroix-Desmazes S, Carbonneil C, Misra N, Donkova V, et al. (2003) Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 101: 758-765 10.1182/blood-2002-05-1447 [doi];2002-05-1447 [pii].
57. Lories RJ, Casteels-Van DM, Ceuppens JL, Van Gool SW, (2004) Polyclonal immunoglobulins for intravenous use induce interleukin 10 release in vivo and in vitro. Ann Rheum Dis 63: 747-748 10.1136/ard.2003.007138 [doi];63/6/747 [pii].
58. Woltman AM, de Fijter JW, Kamerling SW, Paul LC, Daha MR, et al. (2000) The effect of calcineurin inhibitors and corticosteroids on the differentiation of human dendritic cells. Eur J Immunol 30: 1807-1812 10.1002/1521-4141(200007)30:7<1807::AID-IMMU1807>3.0.CO;2-N [pii];10.1002/1521-4141(200007)30:7#60;1807::AID-IMMU1807#62;3.0.CO;2-N [doi].
59. Franchimont D, Martens H, Hagelstein MT, Louis E, Dewe W, et al. (1999) Tumor necrosis factor alpha decreases, and interleukin-10 increases, the sensitivity of human monocytes to dexamethasone: potential regulation of the glucocorticoid receptor. J Clin Endocrinol Metab 84: 2834-2839.
60. Saraiva M, O'Garra A, (2010) The regulation of IL-10 production by immune cells. Nat Rev Immunol 10: 170-181 nri2711 [pii];10.1038/nri2711 [doi].
61. Dougherty GJ, Murdoch S, Hogg N, (1988) The function of human intercellular adhesion molecule-1 (ICAM-1) in the generation of an immune response. Eur J Immunol 18: 35-39 10.1002/eji.1830180107 [doi].
62. Rock KL, Latz E, Ontiveros F, Kono H, (2010) The sterile inflammatory response. Annu Rev Immunol 28: 321-342 10.1146/annurev-immunol-030409-101311 [doi].
63. Morelli AE, Thomson AW (2007) Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol 7.
64. Palucka K, Banchereau J, Mellman I, (2010) Designing vaccines based on biology of human dendritic cell subsets. Immunity 33: 464-478 S1074-7613(10)00367-5 [pii];10.1016/j.immuni.2010.10.007s [doi].
65. Gonzalez N, Bensinger SJ, Hong C, Beceiro S, Bradley MN, et al. (2009) Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. Immunity 31: 245-258 S1074-7613(09)00318-5 [pii];10.1016/j.immuni.2009.06.018 [doi].
66. Norata GD, Pirillo A, Ammirati E, Catapano AL, (2012) Emerging role of high density lipoproteins as a player in the immune system. Atherosclerosis 220: 11-21 S0021-9150(11)00567-3 [pii];10.1016/j.atherosclerosis.2011.06.045 [doi].
67. Zhu X, Westcott MM, Bi X, Liu M, Gowdy KM, et al. (2012) Myeloid cell-specific ABCA1 deletion protects mice from bacterial infection. Circ Res 111: 1398-1409 CIRCRESAHA.112.269043 [pii];10.1161/CIRCRESAHA.112.269043 [doi].
68. Murphy AJ, Woollard KJ, Hoang A, Mukhamedova N, Stirzaker RA, et al. (2008) High-density lipoprotein reduces the human monocyte inflammatory response. Arterioscler Thromb Vasc Biol 28: 2071-2077 ATVBAHA.108.168690 [pii];10.1161/ATVBAHA.108.168690 [doi].
69. Murphy AJ, Westerterp M, Yvan-Charvet L, Tall AR, (2012) Anti-atherogenic mechanisms of high density lipoprotein: Effects on myeloid cells. Biochim Biophys Acta 1821: 513-521 S1388-1981(11)00154-5 [pii];10.1016/j.bbalip.2011.08.003 [doi].
70. Chen Z, O'Neill EA, Meurer RD, Gagen K, Luell S, et al. (2012) Reconstituted HDL elicits marked changes in plasma lipids following single-dose injection in C57Bl/6 mice. J Cardiovasc Pharmacol Ther 17: 315-323 1074248411426144 [pii];10.1177/1074248411426144 [doi].
71. Chen GY, Nunez G, (2010) Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol 10: 826-837 nri2873 [pii];10.1038/nri2873 [doi].
72. De Kimpe SJ, Kengatharan M, Thiemermann C, Vane JR, (1995) The cell wall components peptidoglycan and lipoteichoic acid from Staphylococcus aureus act in synergy to cause shock and multiple organ failure. Proc Natl Acad Sci U S A 92: 10359-10363.
73. Grunfeld C, Marshall M, Shigenaga JK, Moser AH, Tobias P, et al. (1999) Lipoproteins inhibit macrophage activation by lipoteichoic acid. J Lipid Res 40: 245-252.